Paladin, Valeant raise stakes in bidding for Afexa

Canada's Afexa Life Sciences has sparked a bidding war. This morning, Paladin Laboratories topped Valeant Pharmaceuticals' 71-cents-a-share bid with an 81-cent offer, but Valeant turned around and raised its bid to 85 cents. Report

Suggested Articles

AbbVie and Allergan were already jumping through hoops for their merger before a new tax added hundreds of millions to the cost.

Avastin and Herceptin saw U.S. slowdown that's “not very pronounced” after bioisim launched, but Roche execs still warn of "a significant impact.…

Novo Nordisk, which recently completed a wastewater treatment plant for its massive U.S. API site, has made a gift of the $40 million facility.